[시장보고서]세계의 신경통 치료 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 치료별, 적응증별, 유통 채널별, 지역별, 경쟁별(2020-2030년)

세계의 신경통 치료 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 치료별, 적응증별, 유통 채널별, 지역별, 경쟁별(2020-2030년)

Neuralgia Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment, By Indication, By Distribution Channel, By Region & Competition, 2020-2030F

상품코드 : 1698023

리서치사 : TechSci Research

발행일 : 2025년 03월

페이지 정보 : 영문 180 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,500

￦ 6,501,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500

￦ 7,946,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000

￦ 11,558,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

신경통 치료 세계 시장 규모는 2024년 12억 1,000만 달러에 달했고, 2030년까지 예측 기간 동안 연평균 8.84%의 괄목할 만한 성장을 보일 것으로 예상됩니다.

2023년 신경통 치료 세계 시장은 신경통 관련 질환의 진단 및 관리 분야에서 괄목할 만한 성장과 진전을 보일 것으로 예측됩니다. 신경통 치료 세계 시장은 신경 질환의 유병률 증가, 노인 인구 증가, 의약품 개발의 발전, 통증 관리에 대한 인식 증가, 의료 접근성 강화, 삼차 신경통 및 대상포진 후 신경통과 같은 만성 통증 증상에 대한 효과적인 치료에 대한 수요 증가 등의 요인에 의해 주도되고 있습니다. 예를 들어, 호주 정부는 2024년 6월 Medical Research Future Fund를 통해 1,960만 달러(한화 약 190억원)를 지원하여 만성통증과 다학제 진료에 중점을 둔 1차의료 개선을 위해 노력하고 있으며, 880만 달러(한화 약 90억원)는 만성통증 이니셔티브를 지원하고, 농촌 지역에 초점을 맞춘 장애를 완화하고 의료 서비스 접근성과 결과를 개선하기 위한 프로그램을 조정하는 데 초점을 맞추었습니다.

시장 개요
예측 기간	2026-2030년
시장 규모 : 2024년	12억 1,000만 달러
시장 규모 : 2030년	20억 달러
CAGR : 2025-2030년	8.84%
급성장 부문	온라인 약국
최대 시장	북미

시장 성장 촉진요인

신경통 관련 질환의 유병률 증가

주요 시장 이슈

과소진단과 오진

주요 시장 동향

고급 진단 도구

시장 규모와 예측
- 금액별
시장 점유율과 예측
- 치료(약물 요법, 수술)
- 적응증별(당뇨병성 신경병증, 늑간 신경통, 후두 신경통, 말초 신경통, 대상포진 후 신경통, 삼차 신경통)
- 유통 채널별(병원 약국, 온라인 약국, 소매 약국)
- 지역별
- 기업별(2024년)
제품 시장 맵
- 치료별
- 적응증별
- 유통 채널별
- 지역별

제6장 북미의 신경통 치료 시장 전망

시장 규모와 예측
시장 점유율과 예측
북미 : 국가별 분석
- 미국
- 캐나다
- 멕시코

제7장 유럽의 신경통 치료 시장 전망

시장 규모와 예측
시장 점유율과 예측
유럽 : 국가별 분석
- 독일
- 영국
- 프랑스
- 이탈리아
- 스페인

제8장 아시아태평양의 신경통 치료 시장 전망

시장 규모와 예측
시장 점유율과 예측
아시아태평양 : 국가별 분석
- 중국
- 일본
- 인도
- 호주
- 한국

제9장 남미의 신경통 치료 시장 전망

시장 규모와 예측
시장 점유율과 예측
남미 : 국가별 분석
- 브라질
- 아르헨티나
- 콜롬비아

제10장 중동 및 아프리카의 신경통 치료 시장 전망

시장 규모와 예측
시장 점유율과 예측
중동 및 아프리카 : 국가별 분석
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트(UAE)
- 쿠웨이트

제11장 시장 역학

성장 촉진요인
과제

제12장 시장 동향과 발전

최근 동향
인수합병(M&A)
제품 출시

제13장 Porter의 Five Forces 분석

업계내 경쟁
신규 참여 가능성
공급업체의 힘
고객의 힘
대체품의 위협

제14장 경쟁 구도

GSK PLC
Pfizer Inc
Novartis AG
Biogen Inc
Cadila Pharmaceuticals Ltd
Lundbeck Pharmaceuticals Ltd
Zydus Group(Cadila Healthcare Limited)
Eli Lily and Company
Allergan Inc.
Baxter International Inc.

제15장 전략적 제안

제16장 리서치사에 대해 & 면책사항

LSH

영문 목차

영문목차

Global Neuralgia Treatment Market was valued at USD 1.21 billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 8.84% through 2030. The Global Neuralgia Treatment Market in 2023 is characterized by significant growth and advancements in the diagnosis and management of neuralgia-related conditions.The global neuralgia treatment market is driven by factors such as the rising prevalence of neurological disorders, increasing geriatric population, advancements in drug development, growing awareness about pain management, enhanced healthcare access, and the rising demand for effective treatments for chronic pain conditions like trigeminal neuralgia and postherpetic neuralgia. For instance, in June 2024, the Australian Government committed USD 19.6 million from the Medical Research Future Fund to improve primary healthcare, emphasizing chronic pain and multidisciplinary care. USD 8.8 million will support chronic pain initiatives, focusing on rural communities and adapting programs to reduce disability, enhancing healthcare access and outcomes.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 1.21 Billion
Market Size 2030	USD 2.00 Billion
CAGR 2025-2030	8.84%
Fastest Growing Segment	Online Pharmacies
Largest Market	North America

Key Market Drivers

Rising Prevalence of Neuralgia-Related Conditions

Neuralgia, a condition characterized by excruciating pain along nerve pathways, affects millions of individuals worldwide, significantly impacting their quality of life. While neuralgia encompasses various forms, including trigeminal neuralgia, postherpetic neuralgia, and diabetic neuropathy, one common trend is the rising prevalence of neuralgia-related conditions. This growing prevalence represents both a significant challenge and an opportunity for the healthcare industry. According to a 2024 Multiple Sclerosis (MS) Society study, over 150,000 people in the UK are living with multiple sclerosis (MS), with the increase attributed to improved diagnoses and longer life expectancies rather than a higher risk. The regional prevalence is: around 123,000 in England (1 in 450), 6,100 in Wales (1 in 500), 5,300 in Northern Ireland (1 in 350), and 17,400 in Scotland (1 in 300). Annually, more than 7,100 new cases are diagnosed, which averages to about 135 weekly.

Key Market Challenges

Underdiagnosis and Misdiagnosis

A major challenge is the underdiagnosis and misdiagnosis of neuralgia-related conditions. Many individuals endure their symptoms without seeking medical attention, often because they are unaware of their condition or its severity. Misdiagnosis can lead to inappropriate treatments and delays in receiving proper care.

Key Market Trends

Advanced Diagnostic Tools

Early and accurate diagnosis is crucial for effective neuralgia treatment. The development of more sophisticated diagnostic tools, such as high-resolution imaging, nerve conduction studies, and genetic testing, will enable healthcare professionals to identify neuralgia-related conditions with greater precision. Timely diagnosis will lead to more targeted treatments.

Key Market Players

GSK PLC
Pfizer Inc
Novartis AG
Biogen Inc
Cadila Pharmaceuticals Ltd
Lundbeck Pharmaceuticals Ltd
Zydus Group (Cadila Healthcare Limited)
Eli Lily and Company
Allergan Inc.
Baxter International Inc.

Report Scope:

In this report, the Global Neuralgia Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Neuralgia Treatment Market, By Treatment:

Drug-Based
Surgery

Neuralgia Treatment Market, By Indication:

Diabetic Neuropathy
Intercostal Neuralgia
Occipital Neuralgia
Peripheral Neuralgia
Postherpetic Neuralgia
Trigeminal Neuralgia

Neuralgia Treatment Market, By Distribution Channel:

Hospital Pharmacies
Online Pharmacies
Retail Pharmacies

Neuralgia Treatment Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Neuralgia Treatment Market.

Available Customizations:

Global Neuralgia Treatment market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Neuralgia Treatment Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Treatment (Drug-Based, Surgery)
- 5.2.2. By Indication (Diabetic Neuropathy, Intercostal Neuralgia, Occipital Neuralgia, Peripheral Neuralgia, Postherpetic Neuralgia, Trigeminal Neuralgia)
- 5.2.3. By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies)
- 5.2.4. By Region
- 5.2.5. By Company (2024)
5.3. Product Market Map
- 5.3.1. By Treatment
- 5.3.2. By Indication
- 5.3.3. By Distribution Channel
- 5.3.4. By Region

6. North America Neuralgia Treatment Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Treatment (Drug-Based, Surgery)
- 6.2.2. By Indication (Diabetic Neuropathy, Intercostal Neuralgia, Occipital Neuralgia, Peripheral Neuralgia, Postherpetic Neuralgia, Trigeminal Neuralgia)
- 6.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
- 6.2.4. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Neuralgia Treatment Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Treatment
    - 6.3.1.2.2. By Indication
    - 6.3.1.2.3. By Distribution Channel
- 6.3.2. Canada Neuralgia Treatment Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Treatment
    - 6.3.2.2.2. By Indication
    - 6.3.2.2.3. By Distribution Channel
- 6.3.3. Mexico Neuralgia Treatment Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Treatment
    - 6.3.3.2.2. By Indication
    - 6.3.3.2.3. By Distribution Channel

7. Europe Neuralgia Treatment Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Treatment (Drug-Based, Surgery)
- 7.2.2. By Indication (Diabetic Neuropathy, Intercostal Neuralgia, Occipital Neuralgia, Peripheral Neuralgia, Postherpetic Neuralgia, Trigeminal Neuralgia)
- 7.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
- 7.2.4. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Neuralgia Treatment Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Treatment
    - 7.3.1.2.2. By Indication
    - 7.3.1.2.3. By Distribution Channel
- 7.3.2. United Kingdom Neuralgia Treatment Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Treatment
    - 7.3.2.2.2. By Indication
    - 7.3.2.2.3. By Distribution Channel
- 7.3.3. France Neuralgia Treatment Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Treatment
    - 7.3.3.2.2. By Indication
    - 7.3.3.2.3. By Distribution Channel
- 7.3.4. Italy Neuralgia Treatment Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Treatment
    - 7.3.4.2.2. By Indication
    - 7.3.4.2.3. By Distribution Channel
- 7.3.5. Spain Neuralgia Treatment Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Treatment
    - 7.3.5.2.2. By Indication
    - 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Neuralgia Treatment Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Treatment (Drug-Based, Surgery)
- 8.2.2. By Indication (Diabetic Neuropathy, Intercostal Neuralgia, Occipital Neuralgia, Peripheral Neuralgia, Postherpetic Neuralgia, Trigeminal Neuralgia)
- 8.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
- 8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Neuralgia Treatment Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Treatment
    - 8.3.1.2.2. By Indication
    - 8.3.1.2.3. By Distribution Channel
- 8.3.2. Japan Neuralgia Treatment Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Treatment
    - 8.3.2.2.2. By Indication
    - 8.3.2.2.3. By Distribution Channel
- 8.3.3. India Neuralgia Treatment Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Treatment
    - 8.3.3.2.2. By Indication
    - 8.3.3.2.3. By Distribution Channel
- 8.3.4. Australia Neuralgia Treatment Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Treatment
    - 8.3.4.2.2. By Indication
    - 8.3.4.2.3. By Distribution Channel
- 8.3.5. South Korea Neuralgia Treatment Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Treatment
    - 8.3.5.2.2. By Indication
    - 8.3.5.2.3. By Distribution Channel

9. South America Neuralgia Treatment Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Treatment (Drug-Based, Surgery)
- 9.2.2. By Indication (Diabetic Neuropathy, Intercostal Neuralgia, Occipital Neuralgia, Peripheral Neuralgia, Postherpetic Neuralgia, Trigeminal Neuralgia)
- 9.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
- 9.2.4. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Neuralgia Treatment Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Treatment
    - 9.3.1.2.2. By Indication
    - 9.3.1.2.3. By Distribution Channel
- 9.3.2. Argentina Neuralgia Treatment Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Treatment
    - 9.3.2.2.2. By Indication
    - 9.3.2.2.3. By Distribution Channel
- 9.3.3. Colombia Neuralgia Treatment Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Treatment
    - 9.3.3.2.2. By Indication
    - 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Neuralgia Treatment Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Treatment (Drug-Based, Surgery)
- 10.2.2. By Indication (Diabetic Neuropathy, Intercostal Neuralgia, Occipital Neuralgia, Peripheral Neuralgia, Postherpetic Neuralgia, Trigeminal Neuralgia)
- 10.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
- 10.2.4. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Neuralgia Treatment Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Treatment
    - 10.3.1.2.2. By Indication
    - 10.3.1.2.3. By Distribution Channel
- 10.3.2. Saudi Arabia Neuralgia Treatment Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Treatment
    - 10.3.2.2.2. By Indication
    - 10.3.2.2.3. By Distribution Channel
- 10.3.3. UAE Neuralgia Treatment Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Treatment
    - 10.3.3.2.2. By Indication
    - 10.3.3.2.3. By Distribution Channel
- 10.3.4. Kuwait Neuralgia Treatment Market Outlook
  - 10.3.4.1. Market Size & Forecast
    - 10.3.4.1.1. By Value
  - 10.3.4.2. Market Share & Forecast
    - 10.3.4.2.1. By Treatment
    - 10.3.4.2.2. By Indication
    - 10.3.4.2.3. By Distribution Channel

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Product Launches

13. Porter's Five Forces Analysis

13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Products

14. Competitive Landscape

14.1. GSK PLC
14.2. Pfizer Inc
14.3. Novartis AG
14.4. Biogen Inc
14.5. Cadila Pharmaceuticals Ltd
14.6. Lundbeck Pharmaceuticals Ltd
14.7. Zydus Group (Cadila Healthcare Limited)
14.8. Eli Lily and Company
14.9. Allergan Inc.
14.10. Baxter International Inc.